Serine Conjugates of Chlorophyll and Bacteriochlorophyll: Photocytotoxicity *in vitro* and Tissue Distribution in Mice Bearing Melanoma Tumors

V. Rosenbach-Belkin¹, L. Chen², L. Fiedor¹, I. Tregub¹, F. Pavlotsky³, V. Brumfeld¹, Y. Salomon² and A. Scherz^{*1}

¹Department of Biochemistry and

²Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel and

³Department of Dermatology†, Sheba Medical Center, Tel-Hashomer, Israel

Received 26 February 1996; accepted 27 March 1996

ABSTRACT

Chlorophyll (Chl) and bacteriochlorophyll (Bchl) have been made water soluble by transesterification with serine (Ser) at the propionyl residue and tested as potential reagents for photodynamic therapy (PDT). Photocytotoxicity of the conjugates Chl-Ser and Bchl-Ser in M2R mouse melanoma was tested in cell cultures. Tissue uptake and clearance of the photosensitizers in CD1 nude and C57Bl mice implanted with M2R tumors are described. Photocytotoxicity in cell cultures was determined microscopically and by [³H]thymidine incorporation. The LD₅₀ values *in vitro* were 0.05–0.1 μ M for both sensitizers while that of the commercially available hematoporphyrin derivative (HPD, Photosan) was over 100 times higher for the same light intensity (45 mW/cm²). Pigment concentrations were determined fluorometrically in acetone extracts of the tissues of interest at different times after intraperitoneal injection of 20 mg pigment/kg body weight. The distribution pattern of Chl-Ser in the different tissues resembled that reported for Photofrin, chlorin and bacteriochlorin derivatives. Clearance from normal tissues was essentially completed within 16 h for Bchl-Ser and 72 h for Chl-Ser with mean half-lives (*t*_{1/2}) of about 2 and 7 h, respectively. In contrast, the clearance rates of these pigments and their metabolites from melanoma tumor tissue were significantly longer: *t*_{1/2} = 20 h for Chl-Ser and 15 h for Bchl-Ser and metabolites. The clearance rates showed biphasic or single exponential decay patterns in normal tissues and in tumors, respectively. Cumulatively the high phototoxicity, simple mode of delivery and fast tissue clearance rates reported here suggest that polar conjugates of Chl and Bchl promise to be highly effective PDT reagents.

INTRODUCTION

Among the major considerations for introducing new photodynamic therapy (PDT)† agents are their spectral properties, tissue levels attained and their uptake and clearance rates. The last two factors are suggested to depend upon the hydrophilicity/hydrophobicity of the photodynamic reagent (1). Whereas increased hydrophobicity is believed to enhance the pigment's occlusion in the transformed cells, it complicates their delivery and slows down their clearance from normal tissues.

Chlorophylls (Chl) and bacteriochlorophylls (Bchl) are natural pigments with high optical extinction coefficients in the ~660 nm and ~780 nm bands, respectively. In the second wavelength domain, light penetration depth is approximately three times that attained at 630 nm, the wavelength currently used in clinics for photosensitization of Photofrin (2–5). Chlorophyll and Bchl have good yields of excited triplet state with lifetimes similar to those observed for hematoporphyrin derivative (HPD) (30–70%, D. Leupold, personal communication) (5–7) and consequently show antitumor activity *in vivo* after delivery in detergent micelle or liposome vehicles (8). These pigments were also reported to clear from mouse tissues within a few days, significantly faster than Photofrin, thus eliminating potential long-term cutaneous phototoxicity (8–10). Derivatives of Chl and Bchl with enhanced hydrophobicity were prepared and some of them were reported to have high therapeutic potential (1,11,12). At the same time, the hydrolysis product of 2-(1-hexyloxyethyl)-2-devinyl-methyl pyropheophorbide a seems to be a good photosensitizer despite its much higher hydrophilicity (11,13).

Because the spectral characteristics of Chl and Bchl are determined by their macrocycle, it was realized that modifications of peripheral groups that are not conjugated to the macrocycle may further enhance their hydrophilicity while

*To whom correspondence should be addressed at: The Department of Biochemistry, Weizmann Institute of Science, Rehovot 76100, Israel. Fax: 972 8 9344118; e-mail: bcscherz@weizmann.weizmann.ac.il.

© 1996 American Society for Photobiology 0031-8655/96 \$5.00+0.00

†Abbreviations: Bchl, bacteriochlorophyll; Bphe, bacteriopheophytin; Chl, chlorophyll; Chlase, chlorophyllase; HPD, hematoporphyrin derivative; i.p., intraperitoneal; PDT, photodynamic therapy; Phe, pheophytin; PID, propidium iodide (2,7-diamino-9-phenyl-10-[diethylaminopropyl]-phenanthridium iodide); Ser, serine.

retaining their photodynamic activity as in the cases of chlorins, pheophorbides or purpurins (1,11–19). Indeed, hydrolysis of the phytol chain of Chl a and Bchl a enhanced their solubility in aqueous media by several orders of magnitude. Further increase was observed upon esterification of the propionic side chain with polar amino acid residues such as serine and tyrosine (20), while the optical properties and quantum yield for triplet state formation of the Chl/Bchl conjugates were found similar to those of native Chl/Bchl molecules (6). Furthermore, the new compounds showed photodynamic activity both *in vitro* (21) and *in vivo* (20,22,23).

The enhanced hydrophilicity of the Chl/Bchl derivatives may strongly affect their uptake and retention times in tumor and normal tissues and consequently the treatment protocol. Furthermore, it may strongly affect their distribution within the target cells and hence, their photodynamic activity. Therefore, we set out to: (1) compare the photodynamic activity of Chl-Ser and Bchl-Ser with those of commercial HPD, using melanoma cell cultures and (2) determine the tissue distribution of Chl-Ser and Bchl-Ser and their metabolites (when present) at different time intervals after administration to melanoma-bearing mice.

MATERIALS AND METHODS

Photosensitizers. The Chl-Ser and Bchl-Ser were prepared from the natural pigments Chl a and Bchl a, respectively, using *Melia azedarach* L., China tree chlorophyllase (Chlase) (24) as previously described by us (20,25). 1-Methyl ester serine hydrochloride (400 mg, Sigma) and 70 mg ascorbic acid (Merck) were dissolved in 9 mL of water. Using 10 M KOH aqueous solution, the pH of the serine solution was adjusted to 7.7 and 1 mL of 0.5 M sodium phosphate buffer (pH 7.7) was added to maintain the pH during the reaction. Approximately 80 μ L of Triton X-100 are added to achieve a final detergent concentration of 0.8% (vol/vol). In 6 mL of this solution, 200 mg of Chlase acetone powder was homogenized using a Polytron homogenizer. The enzyme suspension was sonicated with 20 mg of solid Bchl a/Chl a, saturated with argon and incubated in the dark for 7 h at 37°C while stirring. For purification the reaction mixture was filtered under vacuum and the residual pigments were washed from the filter paper with acetone. The combined filtrates were then saturated with NaCl and the pigments were extracted with diethyl ether. After drying over NaCl, the solvents were evaporated under vacuum. Any water left was removed by lyophilization. The residue was dissolved in acetone and subjected to column chromatography on CM-Sephadex equilibrated with acetone. The column was washed with acetone to elute unreacted material and then with 5% and 7% methanol (vol/vol) in acetone to elute bacteriochlorophyllide/chlorophyllide and bacteriopheophorbide/pheophorbide. The Bchl-Ser/Chl-Ser were then eluted with 25% methanol in acetone at a yield of 70–80% Bchl-Ser/Chl-Ser relative to the starting Bchl/Chl. The solvent was evaporated and the solid pigments stored under argon at –20°C in the dark until used.

The HPD was the commercially available Photosan-3, supplied at a concentration of 3.3 mg/mL in isotonic NaCl by eeLab. Seehof GmbH D-2244 Wesselburenkoog, Germany, kindly given to us by Dr. J. Moser.

Cell culture. The M2R mouse melanoma cells were cultured as monolayers in Dulbecco's modified Eagle's medium/F12 containing 25 mM HEPES pH 7.4, 10% fetal bovine serum, glutamine 2 mM, penicillin 0.06 mg/mL and streptomycin 0.1 mg/mL at 37°C in a humidified atmosphere of 8% CO₂ as previously described (26).

Cell phototoxicity studies. The M2R mouse melanoma cells (1×10^5 cells/well) were cultured in 24 well microplates and grown for 24 h to about 2×10^5 cells/well, approximately 70–80% confluency. The Chl-Ser or Bchl-Ser were dissolved in culture medium and dispersed by sonication. Photosan was diluted to its final concentration in culture medium. The medium was replaced with serum-free medium and cells were incubated in the dark with the desired

concentration of photosensitizers. Following 2 h of incubation the cells were irradiated at room temperature for 5 min from the bottom of the plate. The medium was replaced by serum containing medium and the culture plates were placed back in the incubator for 24 h. Cytotoxic efficiency in the cell culture was determined by (i) microscopic examination of cell morphology, (ii) fluorescence microscopy of cells following treatment with vital stain (propidium iodide [PID] [2,7-diamino-9-phenyl-10-(diethylaminopropyl)-phenanthridinium iodide methiodide]), which selectively accumulates in nuclei of damaged cells (27) and (iii) [³H]thymidine incorporation as further described below. Control experiments included (1) untreated cells kept in the dark, (2) untreated cells illuminated and (3) cells treated with the drug but kept in the dark.

Light source. The light source for irradiation was a home-built 250 W halogen lamp focused through a 10 cm water filter on a glass support and fitted with a cut-off filter that blocked light under 550 nm in the case of Photosan as a photosensitizer or under 610 nm for cells treated with Chl-Ser and Bchl-Ser. The light dose was adjusted to 45 m W/cm² in all cases.

[³H]thymidine incorporation. Twenty four hours after PDT, cell cultures were pulsed with 1 μ Ci/mL [³H]thymidine for 2 h at 37°C. Cultures were then washed twice with phosphate-buffered saline, treated with 7.5% cold trichloroacetic acid for 30 min at 4°C and washed twice with ethanol. Sodium hydroxide (1 N, 300 μ L/well) was added and the plates were kept for 10 min at 37°C. Samples of 100 μ L were transferred to scintillation vials, neutralized with 100 μ L 1 N HCl and radioactivity was counted by liquid scintillation counting in 4 mL (20:8 [vol/vol]) xylene scintillator lumax mixture according to Chen *et al.* (28).

Animals. All studies were performed on adult C57Bl males (25 $\pm$ 3 g), CD1 nude male (35 $\pm$ 3 g) or female (30 $\pm$ 3 g) mice.

Tumor model. The M2R mouse melanoma cells were maintained as monolayers in tissue culture as described previously (26). Tumors were implanted by subcutaneous injection of 1×10^6 cells/0.1 mL saline on the back of the mouse as described previously (29). In approximately 3–5 weeks, the dark melanotic tumors became visible as solid confined structures with an average diameter of 5–10 mm.

Administration of pigment. The dried pigment aliquot was taken up in a small volume of ethanol and diluted 10 $\times$ in normal saline. The pigments, either Chl-Ser or Bchl-Ser (20 mg/kg body weight) were administered intraperitoneally (i.p.).

Analysis of tissue distribution. At different times after injection, the animals were sacrificed by CO₂ intoxication and tissue samples (epididymal fat, intestine, striated muscle, blood and skin), intact organs (heart, liver, lung, spleen, kidney, brain, testes) and the M2R tumor (0.2–1.0 g) were excised, frozen on dry ice and stored at –20°C until analysis for pigment content was performed.

Determination of pigment concentration in the tissues. The frozen tissue samples were weighed and homogenized with a Polytron (Kinematica GmbH or Ultra-Turrax) in ice-cold acetone under subdued light and subsequently centrifuged at 14 500 g for 15 min at 4°C. The pigment concentrations in the supernatant were estimated by fluorescence spectroscopy using an SLM 8000 spectrofluorometer (Aminco) in a photon-counting mode and expressed per gram of wet weight tissue. The Chl-Ser samples were excited at 416 nm with 4 nm excitation and emission slits and the fluorescence was monitored at 672 nm. The Bchl-Ser samples were excited at 370 nm with 8 nm slits and the fluorescence was monitored at 790 nm. The pigment concentration was determined from the fluorescence intensity data by using calibration plots, obtained by direct measurements of the fluorescence from a series of standard solutions of the analyzed pigment in 2.5% H₂O/acetone. The control extracts prepared from identical tissue samples obtained from untreated mice were used for baseline measurements. The absorption spectra of the different samples recorded on a Spectronics 1201 spectrophotometer provided information concerning the metabolic stability of the injected pigment.

RESULTS AND DISCUSSION

Photocytotoxicity of Chl/Bchl-Ser in M2R mouse melanoma cell cultures

Microscopic evaluation. In order to evaluate light-dependent cytotoxicity of Chl-Ser we first treated M2R melanoma cell

Figure 1. Photocytotoxicity of Chl-Ser: microscopic determination. Phase-contrast (a) or fluorescence microscopy (b) of one image of M2R cells monolayers incubated for 1 h with 1 μ M Chl-Ser and irradiated for 5 min. Indicated are the unilluminated area covered with aluminum foil (Dark) and the illuminated area (Light). Magnification 900 $\times$ using a Zeiss Axiovert 35 inverted microscope with rhodamine optics. Cells in the dark area have a normal shape (a) and exclude the vital stain PID (b). Cells in the illuminated area (Light) appear damaged (a) and their nuclei become stained with PID (b).

cultures with 1 μ M of the pigment for 1 h. Following replacement of the medium, the experimental culture plates were illuminated with a half area covered with aluminum foil (as dark control) and further kept under normal culture conditions for 24 h (Fig. 1a,b). Microscopic examination of the cultures indicated that cells in the illuminated regions (marked "Light") became partially detached and the remaining cells appeared morphologically damaged (Fig. 1a, phase-contrast micrograph, light area) and became all positively stained by PID (Fig. 1b fluorescence micrograph, light area). In contrast, cells in the shadowed area (served as "Dark" controls) appeared normal (Fig. 1a, dark area) and excluded the dye (Fig. 1b dark area). Cells in illuminated untreated controls appeared identical to untreated or dark-treated control cultures.

[3 H]thymidine incorporation. In order to quantify the light-dependent cytotoxicity of the new Chl derivatives, cell cultures were incubated at increasing concentrations of Chl-Ser or Bchl-Ser (Fig. 2) and the effects on [3 H]thymidine incorporation were determined. In comparison we also de-

Figure 2. Photocytotoxicity of Chl-Ser, Bchl-Ser and Photosan: M2R cell survival determined by [3 H]thymidine incorporation. [3 H]thymidine incorporation in M2R cells following treatment with the indicated photosensitizer concentrations (Bchl-Ser, Chl-Ser and Photosan) in the dark or after illumination (5 min) is shown. Cell survival is given as [3 H]thymidine incorporation (2 h pulse) performed 24 h after photodynamic treatment relative to untreated controls. Values are the mean $\pm$ SD of 8, 2 and 7 experiments, respectively, performed by duplicate determinations each.

termined photocytotoxicity of Photosan under the same conditions (Fig. 2). It can be seen that cytotoxicity of both pigment derivatives (Chl-Ser and Bchl-Ser) is absolutely light and dose dependent. The effective concentration range is in the submicromolar range, over 100 times lower than that displayed by HPD. Noteworthy is the fact that the LD₅₀ values of the water-soluble Chl and Bchl conjugates are lower by an order of magnitude from values reported for the analogues hydrophobic methyl esters of Bchl and its free acid analog bacteriopheophytin (Bphe) applied to M2R mouse melanoma cell cultures (30).

Biodegradation of Chl-Ser

The absorption spectra of acetone extracts obtained from some of the tissues 12–72 h after injection were characterized by two optical transitions at 510 and 545 nm in addition to the typical Chl absorption profile. These additional bands appeared similar to those of pheophytin a (Phe a), the demetallized derivative of Chl a (31), which has its lowest energy transition at wavelengths similar to that of Chl-Ser. This result suggested that small amounts of Chl-Ser were converted to the Phe a derivative *in vivo*. The Phe a derivative by itself is likely to be photodynamically active (8). Therefore fluorometric determinations of total pigment concentrations were performed by excitation at 416 nm where equal concentrations of both pigments (Chl-Ser and Phe-Ser) maintain the same fluorescence peak intensities at 672 nm.

Distribution of Chl-Ser in mouse tissues

The Chl-Ser distribution in tissues of CD1 mice was studied between 2 to 72 h after i.p. injection of 20 mg Chl-Ser/kg body weight (Fig. 3, Table 1). The time-dependent changes in tissue pigment concentration indicated that maximal levels of Chl-Ser in most tissues were reached within 2 h, the earliest time point sampled after injection. Much slower uptake rates were seen in skin and tumor where pigment peak levels reached maxima only at 12 and 5 h after injection, respectively. The relative distribution of Chl-Ser among different tissues in nude mice is qualitatively similar to that reported for Photofrin (32) and other sensitizers (13,33). Thus, kidney and the reticuloendothelial cell-containing organs like liver

Figure 3. Distribution of Chl-Ser in mouse tissues at various times after i.p. injection. Concentration of Chl-Ser in tissues of CD1 nude male mice at different times after injection (six mice for each time point) of 20 mg Chl-Ser/kg body weight. Values represent the mean concentration with standard deviation.

and spleen accumulated relatively high concentrations of Chl-Ser, (9.14, 44.7 and 8.63 $\mu\text{g/kg}$ body weight, respectively) (Table 1), whereas melanoma tumor and brain accumulated low amounts of Chl-Ser (2.64 and 0.48 $\mu\text{g/kg}$ body weight, respectively). The high uptake levels of Chl-Ser in fat tissue (27.3 $\mu\text{g/kg}$ body weight) are likely to result from the high solubility of the pigment in hydrophobic environments, a result that agrees well with the partition ratio of Chl-Ser in water:octanol, which we determined to be 1: 9. However, following this argument, higher pigment levels would be expected in the brain. Therefore, the observed low pigment level in the brain (0.48 $\mu\text{g/kg}$ body weight) probably reflects the combination of the large volume of distri-

bution of Chl-Ser, low cerebral blood flow and impermeability of the blood-brain barrier (34).

Clearance of Chl-Ser from the different tissues showed a biphasic kinetic pattern upon semilogarithmic plotting of pigment concentrations as a function of time. The first phase consisted of a relative fast exponential decay where 90% of the pigment cleared within 40 h after injection with a half-life ($t_{1/2}$) in the range of 5–11 h (Table 1). Because only two time points (48 and 72 h) were recorded in the second phase, no $t_{1/2}$ values were calculated. Yet the trend indicated by these two points suggests a much slower clearance rate in the later phase. In contrast we found that within the experimental time interval (up to 72 h), the pigment cleared from

Table 1. Time points of peak levels, half-life of clearance and tissue pigment concentrations following i.p. administration of 20 mg Chl-Ser/kg body weight to CD1 nude male mice

Organ	Peak (h)	$t_{1/2}^*$ (h)	Concentration [†] ($\mu\text{g/g}$ wet tissue)		
			At peak time [‡]	At 24 h	At 48 h
Heart	2	7	5.12 ± 0.43	0.49 ± 0.07	0.15 ± 0.02
Liver	2	5	44.7 ± 11.7	2.26 ± 0.40	0.55 ± 0.07
Lung	2	6	8.40 ± 0.95	0.74 ± 0.09	0.35 ± 0.10
Spleen	2	9	8.63 ± 1.56	1.43 ± 0.35	0.79 ± 0.17
Kidney	2	8	9.14 ± 1.02	1.44 ± 0.07	0.32 ± 0.04
Brain	2	7	0.48 ± 0.09	0.04 ± 0.01	0.02 ± 0.01
Skin	12	9	3.53 ± 0.60	0.91 ± 0.19	0.21 ± 0.05
Testes	2	6	5.08 ± 0.72	0.37 ± 0.08	0.08 ± 0.02
Blood	2	11	8.43 ± 0.56	1.81 ± 0.22	1.09 ± 0.10
Muscle	2	7	3.83 ± 2.01	0.38 ± 0.03	0.05 ± 0.02
Fat	2	5	27.3 ± 4.34	1.02 ± 0.20	0.29 ± 0.06
Tumor	5	20	2.64 ± 0.75	1.29 ± 0.23	0.64 ± 0.24

*The $t_{1/2}$ values were extracted from semilogarithmic plots describing pigment concentrations as a function of time after injection.

[†]Concentration of Chl-Ser ($\mu\text{g/g}$ wet tissue) in each tissue is an average of six mice $\pm$ SD.

[‡]Peak time indicates the time point for maximum recorded pigment level of each tissue.

the tumor in a single slow exponential decay with a half-life of 20 h. The longer retention time of Chl-Ser in the tumor compared to the other tissues suggests that in the case of melanoma the relatively high retention time may allow for tissue selectivity in PDT in a way that resembles observations made with HPD (35). The basis for this phenomenon is not clear but could be due to the combination of enhanced permeability of the tumor's vasculature and the possibility that solid tumors that contain necrotic regions may act as a sink. The specific case of melanoma adsorption of the pigment to melanin may further enhance the sink effect.

Although the clearance rates from all tissues (except the tumor) are of the same order of magnitude, the Chl-Ser levels attained vary significantly in each. Thus, at 2 h after injection only the brain contains a lower pigment concentration than the tumor (see concentration at peak time) (Table 1). However, at 24 h only the liver, kidney, blood and spleen had higher Chl-Ser levels than the tumor. At the same time the heart, lung, brain, skin, testes, muscle and fat all contained less pigment/gram tissue than the tumor (Table 1). Consequently, the concentration ratio of pigment in the tumor relative to other organs apart from blood showed an apparent increase with time, reaching a maximum >1 (for most tissues) at 48 h after injection. The concentration ratio of pigment in the tumor relative to the blood had peaked at 24 h after injection.

One of the most important conclusions of this study is that by 72 h after injection (the longest recorded time), nearly 100% of the pigment and its metabolites had cleared from all tissues. Bellinier and coworkers determined the distribution and clearance of the [^{14}C] radioisotopically-labeled equivalent of Photofrin in DBA/2 Ha-DD mice. They reported retention of [^{14}C] activity in the animal tissues for extended time periods (>192 h) after drug administration where a large part of the radioactivity is accounted to Photofrin (36). Peng and coworkers, using fluorescence methods, reported that the concentration of Photofrin was highest in different organs or tissues of BALB/c nude mice 12–72 h after injection with clearance half-lives of about 30 h (37). Thus the short retention time of Chl-Ser in mouse tissues in both relative and absolute terms may be of great advantage in clinical applications of PDT as compared to Photofrin. The use of Photofrin is presently limited by its very low clearance rates, subjecting patients to severe skin photosensitivity for excessively long periods of time (of the order of weeks to months) after administration of the drug (38).

Two additional experiments with male CD1 nude mice were performed, one using 24 males and one using 30 males and 30 females treated with 20 mg Chl-Ser/kg body weight. In all three experiments we obtained similar results and no significant differences were observed between males or females. Similar results were also obtained in one experiment performed with 26 C57 black male mice.

Biodegradation of Bchl-Ser

Spectra (absorption and fluorescence) of acetone extracts obtained after Bchl-Ser administration pointed to lower chemical stability in all tissues when compared to Chl-Ser. The optical absorption spectra of the Bchl-Ser in tissue acetone extracts including those prepared from melanoma tumors de-

Figure 4. *In vivo* degradation of Bchl-Ser in mouse liver. Spectra of acetone extracts of (a) mouse liver extract 6 h after administration of 20 mg Bchl-Ser/kg body weight (in 5 cm cuvette) and (b) 1.62×10^{-5} M Bchl-Ser (in a 1 cm cuvette).

picted two additional transitions at 525 nm and 680 nm as seen in the depicted liver extract (Fig. 4a). The 525 nm absorption band characterizes the Q_x transition of the demetallized product (Bphe) (39), for which the Q_y absorption is at 750 nm and the fluorescence peaks at 765 nm. The 680 nm absorption probably results from the presence of oxidation products that fluoresce at 690 nm. A similar phenomenon was previously reported in DBA/2Ha and C3H/HeJ mice for native Bchl *in vivo* (8). The content of Bchl-Ser oxidation products in the tissue extracts is expressed in fluorescence units and not in units of concentration as the identity of this material is presently unknown.

Distribution of Bchl-Ser in mouse tissues

The Bchl-Ser distribution in mouse tissues was studied for time periods ranging from 1 to 16 h after i.p. injection of 20 mg Bchl-Ser/kg body weight (Fig. 5, Table 2). Most tissues including the melanoma tumor reached peak levels of Bchl-Ser within ~ 1 h (tests 2 h, muscle 1–2 h) after injection. By 16 h after injection (the longest recorded time), nearly 100% of the pigment had cleared from all tissues.

The time-dependent decline in Bchl-Ser concentration in the different tissues reflects both degradation (to Bphe and oxidation products) and vascular transport. Thus, during the first 4–6 h (concerning 65% of peak pigment levels in the tumor and 90% in the other tissues) the decline in pigment concentrations could be fitted by the same exponential curve in all tissues. The corresponding $t_{1/2}$ values were in the range of 1.5–3 h (Table 2) including the tumor. The residual Bchl-

Figure 5. Distribution of Bchl-Ser in mouse tissues at various times after i.p. injection. Concentration of Bchl-Ser (●—●) and Bphe-Ser (○—○) and relative fluorescence of oxidation products (▲—▲) in tissues of CD1 nude male mice at different times after injection (five mice for each time point) of 20 mg Bchl-Ser/kg body weight. Values represent the mean concentration with standard deviation.

Ser (35% of peak pigment levels in the tumor and 10% in the other tissues) seemed to clear much slower.

The peak concentration values of the Bchl-Ser metabolites (Bphe-Ser and oxidation products) vary from 1 to 6 h. Their half-lives in the tumor were 7 h for the Bphe-Ser and ~15 h for oxidation products, much longer than in other tissues (2–4 h, Table 2). The reasons for the relatively longer retention times of Bchl-Ser and its photoactive metabolites in the tumor are likely to be similar to those suggested above for Chl-Ser. In addition, like Bchl-Ser, by 16 h after injection most of the degradation products had cleared from healthy tissues. The Bphe-Ser concentration at early time points (1 h) was found to be relatively low in liver, skin, blood and tumor when compared to intestines, fat, testes and kidney. The differences in the peak time values and relative concentrations of Bphe-Ser are likely to reflect the differences in the nature of the respective tissue, *i.e.* pH, pO_2 , hydropho-

bicity, susceptibility to tissue-specific degradation enzymes and the extent of the vasculature.

Two additional experiments were performed on CD1 nude mice treated with 20 mg Bchl-Ser/kg body weight, one with 12 female and 7 male mice and one involving 24 male mice. The results of these experiments were essentially identical to the one described in Fig. 5 and Table 2.

Chlorophyllous pigments appear attractive for PDT and are superior to the presently used HPD. The shorter retention of these pigment derivatives in the circulation is expected to minimize the serious side effect of cutaneous phototoxicity, presently a major drawback of Photofrin-based PDT. Yet, structure/function relationships, in particular, the role of hydrophobicity, have not been fully resolved (11). This paper addresses the cell phototoxicity and biodistribution of hydrophilic novel Chl/Bchl conjugates. Extremely high phototoxicity, short retention times *in vivo* and simple mode of drug

Table 2. Time point of peak levels, pigment concentration at peak time and half-life of Bchl-Ser, Bphe-Ser and oxidation products following i.p. administration of 20 mg Bchl-Ser/kg body weight to CD1 nude male mice*

Organ	Bchl-Ser			Bphe-Ser			Oxidation products	
	Peak (h)	Concentration at peak time	t _{1/2} (h)	Peak (h)	Concentration at peak time	t _{1/2} (h)	Peak (h)	t _{1/2} (h)
Heart	1	1.40 ± 0.13	2	1	0.30 ± 0.04	2.5	2	4
Liver	1	7.0 ± 1.25	1.5	2	1.22 ± 0.48	2	2	3
Lung	1	1.63 ± 0.09	2	1	0.35 ± 0.04	3	2	6
Spleen	1	7.37 ± 3.25	1.5	1	1.63 ± 1.0	2	1	2
Kidney	1	3.71 ± 0.31	1.5	1–2	0.63 ± 0.18	4	2	3
Brain	1	0.09 ± 0.01	3	4	0.02 ± 0.01	2	4	4.5
Skin	2	0.57 ± 0.14	3	2	0.06 ± 0.01	3.5	6	—
Intestine	1	5.50 ± 0.92	1.5	4	3.67 ± 1.12	2.5	4	3.5
Blood	1	1.16 ± 0.46	1.5	1	0.11 ± 0.07	2.5	2	2
Muscle	1–2	0.33 ± 0.05	2.5	2	0.12 ± 0.06	3	2	3
Fat	1	6.47 ± 1.23	2	2	2.03 ± 0.29	2	2	3.5
Testes	2	3.21 ± 1.4	1.5	2	0.84 ± 0.23	1.5	2	1.5
Tumor	1	0.5 ± 0.12	2	2	0.07 ± 0.03	7	2	~15

*Peak time indicates the time point of maximum recorded pigment level of each tissue. The t_{1/2} values were extracted from semilogarithmic plots describing pigment concentrations (or fluorescence) as a function of time after injection. Concentration of the pigments (µg/g wet tissue, Bchl-Ser and Bphe-Ser) in each tissue is an average of five mice ± SD.

delivery of both Chl-Ser and Bchl-Ser in addition to their superior spectral properties are of significant advantage for potential application of these pigments in PDT when compared to Photofrin and the water-insoluble Bchl and Bphe.

The presented results indicate that Bchl-Ser- or Chl-Ser-based PDT has to be performed at early time windows, only a few hours following drug administration to coincide with maximal tissue levels of the drug using a weaker light source. Consequently, the entire treatment protocol is expected to become shorter with significant clinical advantages. The reason for the high *in vitro* photocytotoxicity of Chl/Bchl-Ser compared to the Bphe-methyl esters is presently under study.

Acknowledgements—We thank Asaf Rudich for his devoted help. Y.S. is the incumbent of the Charles and Tillie Lubin chair of Biochemical Endocrinology. This study was supported in part by grants from The Lynne and William Frankel Fund for the Diagnosis and Treatment of Ovarian and Breast Cancer, The Jaffe family foundation, The Ministry of Science and Technology Israel, the Commission of the European Communities and Yeda Research and Development Co. Ltd. Israel.

REFERENCES

- Pandey, R. K., F.-Y. Shiau, A. B. Sumlin, T. J. Dougherty and K. M. Smith (1994) Syntheses of new bacteriochlorins and their antitumor activity. *Bioorg. Med. Chem. Lett.* **4**, 1263–1267.
- Svaasand, L. O. (1984) Optical dosimetry for direct and interstitial photoradiation therapy of malignant tumors. In *Porphyrin Localization and Treatment of Tumors* (Edited by D. R. Doiron and C. J. Gomer), pp. 91–114. Liss, New York.
- Doiron, D. R. (1984) Photophysics and instrumentation for porphyrin detection and activation. In *Porphyrin Localization and Treatment of Tumors* (Edited by D. R. Doiron and C. J. Gomer), pp. 41–73. Liss, New York.
- Wilson, B. C., W. P. Jeeves and D. M. Lowe (1985) *In vivo* and post mortem measurements of the attenuation spectra of light in mammalian tissue. *Photochem. Photobiol.* **42**, 153–162.
- Amato, I. (1993) Hope for a magic bullet that moves at the speed of light. *Science* **262**, 32–33.
- Fiedor, L., A. A. Gorman, I. Hamblett, V. Rosenbach-Belkin, Y. Salomon, A. Scherz and I. Tregub (1993) A pulsed laser and pulse radiolysis study of amphiphilic chlorophyll derivatives with PDT activity toward malignant melanoma. *Photochem. Photobiol.* **58**, 506–511.
- Krasnovskii, A. A., Jr., I. V. Vichegzhana, N. N. Drozdova and A. A. Krasnovskii (1985) Generation and quenching of singlet molecular oxygen by bacteriochlorophyll and bacteriopheophytin a and b. *Dokl. Akad. Nauk SSSR* **283**, 474–477.
- Henderson, B. W., A. B. Sumlin, B. L. Owczarczak and T. J. Dougherty (1991) Bacteriochlorophyll-a as photosensitizer for photodynamic treatment of transplantable murine tumors. *J. Photochem. Photobiol. B Biol.* **10**, 303–313.
- Henderson, B. W. and G. Farrell (1989) Possible implication of vascular damage for tumor cell inactivation *in vivo*: comparison of different photosensitizers. *Proc. SPIE Int. Soc. Opt. Eng.* **1065**, 2.
- Dougherty, T. J. and A. B. Sumlin (1989) Chlorophyll and bacteriochlorophyll as potential photosensitizers in PDT. In *Photodynamic Therapy: Mechanisms*. Los Angeles. [Abstract]
- Pandey, R. K., F.-Y. Shiau, A. B. Sumlin, T. J. Dougherty and K. M. Smith (1992) Structure/activity relationships among photosensitizers related to pheophorbides and bacteriopheophorbides. *Bioorg. Med. Chem. Lett.* **2**, 491–496.
- Pandey, R. K., S. Constantine, D. A. Goff, A. N. Kozyrev, T. J. Dougherty and K. M. Smith (1996) Chlorophyll-a derivatives in photodynamic therapy: effect of position of heptyl ether side-chains on *in vivo* photosensitizing activity. *Bioorg. Med. Chem. Lett.* **6**, 105–110.
- Bellnier, D. A., B. W. Henderson, R. K. Pandey, W. R. Potter and T. J. Dougherty (1993) Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a. *J. Photochem. Photobiol. B Biol.* **20**, 55–61.
- Lee, S.-J. H., N. Jagerovic and K. M. Smith (1993) Use of the chlorophyll derivative, purpurin-18, for syntheses of sensitizers for use in photodynamic therapy. *J. Chem. Soc. Perkin Trans. I*, 2369–2377.
- Moser, J. G. (1993) Attempts to treat malignant melanoma by photodynamic therapy using bacteriopheophorbide ester as a sensitizer. *SPIE Conf. Proc.* **1881**, 116–125.
- Hoover, J. K., T. W. Sery and N. Yamamoto (1988) Photodynamic sensitizers from chlorophyll: purpurin-18 and chlorin p6. *Photochem. Photobiol.* **48**, 579–582.
- Spikes, J. D. (1990) Chlorins as photosensitizers in biology and medicine. *J. Photochem. Photobiol. B Biol.* **6**, 259–274.
- Kessel, D. and K. Smith (1989) Photosensitization with derivatives of chlorophyll. *Photochem. Photobiol.* **49**, 157–160.
- Röder, B. (1990) Photosensitizing properties of phorbides. *J. Photochem. Photobiol. B Biol.* **5**, 519–521.

20. Scherz, A., Y. Salomon and L. Fiedor (1994) Chlorophyll and bacteriochlorophyll derivatives, preparation and pharmaceutical compositions comprising them as photosensitizers for photodynamic therapy. *Chem. Abst.* **120**, 386.
21. Tregub, I., J. Schmidt-Sole, J. DeJordy, V. Rosenbach-Belkin, V. Brumfeld, L. Fiedor, Y. Salomon and A. Scherz (1992) Application of chlorophyll and bacteriochlorophyll derivatives to PDT of malignant melanoma. In *Proceedings of the Second International Congress on Interaction of Light with Biological Systems* (Edited by M. Holick and A. Kligman), pp. 354–361. W. de Gruyter, New York.
22. Zilberstein, J., A. Scherz, A. Bromberg, P. Bendel, M. Neeman and Y. Salomon (1994) Chlorophyll based PDT of melanoma: follow up by MRI and by tissue inserted oxygen sensor. In abstract book of the conference: *The Tumor Microenvironment: Its Characterization, Modification and Clinical Implication*. Faculty of Medicine, University of Granada, Granada, Spain.
23. Zilberstein, J., A. Scherz, A. Bromberg, P. Bendel, M. Neeman and Y. Salomon (1995) Mechanisms involved in chlorophyll based photoinduced cell damage: photodynamic therapy of melanoma. *Proc. Soc. Magn. Reson.* **3**, 1681.
24. Amir-Shapira, D., E. E. Goldschmidt and A. Altman (1987) Chlorophyll catabolism in senescing plant tissues: *in vitro* breakdown intermediates suggest different degradative pathways for citrus fruit and parsley leaves. *Proc. Natl. Acad. Sci. USA* **84**, 1901–1905.
25. Fiedor, L. (1994) Modified chlorophylls as models for primary photosynthesis and photosensitizers for photodynamic therapy of cancer. Ph.D. Thesis, Weizmann, Institute of Science, Rehovot, Israel.
26. Gerst, J. E., J. Sole, J. P. Mather and Y. Salomon (1986) Regulation of adenylate cyclase by β -melanotropin in the M2R melanoma cell line. *Mol. Cell. Endocrinol.* **46**, 137–147.
27. Yeh, C.-J. G., B.-L. Hsi and W. P. Faulk (1981) Propidium iodide as a nuclear marker in immunofluorescence. II. Use with cellular identification and viability studies. *J. Immunol. Methods* **43**, 269–275.
28. Chen, L., Y. Mory, A. Zilberstein and M. Revel (1988) Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon. *Proc. Natl. Acad. Sci. USA* **85**, 8037–8041.
29. DeJordy, J. O., P. Bendel, A. Horowitz, Y. Salomon and H. Degani (1992) Correlation of MR imaging and histologic findings in mouse melanoma. *J. Magn. Reson. Imag.* **2**, 695–700.
30. Moser, J. G., A. Ostrowsky, M. Gümüşdaglı and B. Kleiber (1994) Bacteriopheophorbide esters: photosensitizers without “threshold dose”? *EUROPTO Conf. Proc.* **2078**, 193–204.
31. Hoff, A. J. and J. Ames (1991) Visible absorption spectroscopy of chlorophylls. In *Chlorophylls* (Edited by H. Scheer), pp. 723–738. CRC Press, Boca Raton, FL.
32. Dougherty, T. J. (1992) Photochemistry in the treatment of cancer. *Adv. Photochem.* **17**, 275–311.
33. Henderson, B. W. and T. J. Dougherty (1992) How does photodynamic therapy work? *Photochem. Photobiol.* **55**, 145–157.
34. Benet, L. Z., J. R. Mitchell and L. B. Sheiner (1991) General principle. In *Goodman and Gilman's The Pharmacological Basis of Therapeutics* (Edited by A. G. Gilman, T. W. Rall, A. S. Nies and P. Taylor), pp. 10–11. McGraw-Hill, New York.
35. Pantelides, M. L., J. V. Moore and N. J. Blavklovk (1989) A comparison of serum kinetics and tissue distribution of Photofrin II following intravenous and intraperitoneal injection in the mouse. *Photochem. Photobiol.* **49**, 67–70.
36. Bellinier, D. A., Y.-K. Ho, R. K. Pandey, J. R. Missert and T. J. Dougherty (1989) Distribution and elimination of Photofrin II in mice. *Photochem. Photobiol.* **50**, 221–228.
37. Peng, Q., J. Moan, M. Kongshaug, J. F. Evensen, H. Anholt and C. Rimington (1991) Sensitizer for photodynamic therapy of cancer: a comparison of the tissue distribution of Photofrin II and aluminum phthalocyanine tetrasulfonate in nude mice bearing a human malignant tumor. *Int. J. Cancer* **48**, 258–264.
38. Bellinier, D. A. and T. J. Dougherty (1989) Protection of murine foot tissue and transplantable tumor against Photofrin-II-mediated photodynamic sensitization with WR-2721. *J. Photochem. Photobiol. B Biol.* **4**, 219–225.
39. Scheer, H. (1991) Structure and occurrence of chlorophylls. In *Chlorophylls* (Edited by H. Scheer), pp. 3–30. CRC Press, Boca Raton, FL.